A novel methodology was used successfully in the non-invasive evaluation of the mutation frequency of the PIK3CA gene in circulating tumour cells (CTCs) found in the blood of patients with metastatic hormone receptor-positive breast cancer, according to findings presented during an abstracts session at the IMPAKT Breast Cancer Conference held 7–9 May, 2015 in Brussels, Belgium.

Click here to read the article in full.

Source: ESMO